As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.
GSK's next-generation respiratory drugs and HIV drugs look poised for strong growth over the next three years.
HIV patent pressure to GSK's key drugs will likely begin in 2027, setting up a major hurdle for growth later in the decade.
|
Metric
|
GSK
|
MRK
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.60 | 84.47 | 14.31 |
Price/Book Value | 4.77 | 8.54 | 1.67 |
Price/Sales | 2.23 | 5.37 | 2.54 |
Price/Cash Flow | 10.62 | 21.22 | 13.66 |
|
Metric
|
GSK
|
MRK
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.59 | 0.68 | 0.58 |
Current Ratio | 0.88 | 1.25 | 0.91 |
Interest Coverage | 9.30 | 2.33 | 0.74 |
|
Metric
|
GSK
|
MRK
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 10.54% | 3.59% | 4.98% |
Return on Equity (Normalized) | 50.48% | 9.12% | 10.90% |
Return on Invested Capital (Normalized) | 21.33% | 5.88% | 7.28% |
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Xdpvglcbk | Kqlrx | $713.8 Bil | |
JNJ
| Johnson & Johnson | Gsqpkcy | Bnq | $361.9 Bil | |
MRK
| Merck & Co Inc | Cvsjlbqpy | Pll | $319.6 Bil | |
ABBV
| AbbVie Inc | Xsycbtkl | Dwpyw | $286.3 Bil | |
AZN
| AstraZeneca PLC ADR | Btxtbqqwz | Srhb | $213.0 Bil | |
RHHBY
| Roche Holding AG ADR | Lxknmytcbl | Mckm | $198.4 Bil | |
NVS
| Novartis AG ADR | Hfgqrygy | Tssk | $193.5 Bil | |
PFE
| Pfizer Inc | Lwwbgqk | Kfrx | $146.7 Bil | |
AMGN
| Amgen Inc | Gctxlwwyk | Vfvt | $142.3 Bil | |
SNY
| Sanofi SA ADR | Qpdzrqp | Gbh | $116.2 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)